This brand name is authorized in Austria, Brazil, Canada, Cyprus, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Japan, Malta, Mexico, Netherlands, New Zealand, Poland, Singapore, South Africa, Spain, Tunisia, Turkey, UK.
The drug EMLA contains a combination of these active pharmaceutical ingredients (APIs):
1
|
UNII
98PI200987 - LIDOCAINE
|
|
Lidocaine, like other local anaesthetics, causes a reversible blockade of impulse propagation along nerve fibres by preventing the inward movement of sodium ions through the nerve membrane. Local anaesthetics of the amide-type are thought to act within the sodium channels of the nerve membrane. |
|
2
|
UNII
046O35D44R - PRILOCAINE
|
|
Prilocaine is a toluidine derivative and intermediate-acting amino amide with local anesthetic property. Prilocaine binds to the intracellular surface of sodium channels which blocks the subsequent influx of sodium into the cell. Action potential propagation and never function is, therefore, prevented. This block is reversible and when the drug diffuses away from the cell, sodium channel function is restored and nerve propagation returns. |
|
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| D04AB01 | Lidocaine | D Dermatologicals → D04 Antipruritics, incl. antihistamines, anesthetics, etc. → D04A Antipruritics, incl. antihistamines, anesthetics, etc. → D04AB Anesthetics for topical use |
| N01BB04 | Prilocaine | N Nervous system → N01 Anesthetics → N01B Anesthetics, local → N01BB Amides |
| N01BB20 | Combinations | N Nervous system → N01 Anesthetics → N01B Anesthetics, local → N01BB Amides |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| BR | Câmara de Regulação do Mercado de Medicamentos | 505618100044717, 505618100044817 |
| CA | Health Products and Food Branch | 00886858, 02057794 |
| EE | Ravimiamet | 1075306, 1151446, 1163843, 1257375, 1782301 |
| ES | Centro de información online de medicamentos de la AEMPS | 61096 |
| FI | Lääkealan turvallisuus- ja kehittämiskeskus | 007784, 447300, 447557, 528869 |
| FR | Base de données publique des médicaments | 63396602, 67458460 |
| GB | Medicines & Healthcare Products Regulatory Agency | 194666, 194667, 29374, 399390, 76684 |
| HK | Department of Health Drug Office | 27892 |
| IL | מִשְׂרַד הַבְּרִיאוּת | 2535 |
| JP | 医薬品医療機器総合機構 | 1219800N1023, 1219800S1027 |
| MT | Medicines Authority | MA955/01001, PI1438/05801A, PI908/15602A |
| MX | Comisión Federal para la Protección contra Riesgos Sanitarios | 120M98, 375M2002 |
| NL | Z-Index G-Standaard, PRK | 25321, 39667 |
| NZ | Medicines and Medical Devices Safety Authority | 4617, 4618 |
| PL | Rejestru Produktów Leczniczych | 100021795, 100082578, 100255895, 100262990, 100289256, 100308893, 100334198, 100358342, 100372069, 100413584, 100425819, 100429591, 100436496, 100450889, 100453000, 100459723, 100468510 |
| SG | Health Sciences Authority | 06443P |
| TN | Direction de la Pharmacie et du Médicament | 5103061 |
| TR | İlaç ve Tıbbi Cihaz Kurumu | 8699874080502 |
| ZA | Health Products Regulatory Authority | 30/4/0478, Z/4/51 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.